share_log

Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.

Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.

在Biogen和Elsai宣布将Lecanemab治疗作为主要终点并减少全球认知和功能规模的临床下降之后,拥有阿尔茨海默氏症计划的公司的股票正在交易。
Benzinga ·  2022/09/28 19:41

Shares of companies with Alzheimer's programs are trading after Biogen and Elsai announced Lecanemab treatment its the primary endpoint and reduced clinical decline on the global cognitive and functional scale.

在Biogen和Elsai宣布将Lecanemab治疗作为主要终点并减少全球认知和功能规模的临床下降之后,拥有阿尔茨海默氏症计划的公司的股票正在交易。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发